Niijima K, Niijima Y, Okada S, Yamada M

Language: English
References: 9
Page: 308-311
PDF size: 113.94 Kb.

ABSTRACT

A 75-year old male patient had been regularly visiting our hospital for the management of his type 2 diabetes mellitus since he was diagnosed at age 64 years. When he developed hypoglycemic episodes with sulfonylurea, ipragliflozin (50 mg/day) was started to replace the sulfonylurea therapy. However, 49 days after starting ipragliflozin, his AST increased from 13 to 622 U/L, ALT increased from 9 to 266 U/L, ALP increased from 239 to 752 U/L, and γ-GTP increased from 19 to 176 U/L. ZTT was 3.5 U, TTT was 0.4 U, and total bilirubin was 0.7 mg/dL. IgM hepatitis A antibody, hepatitis B antigen, hepatitis C virus antibody, IgM CMV antibody, and IgM EB VCA antibody were negative, whereas a lymphocyte transformation test for ipragliflozin was positive. Abdominal CT scan showed mild fatty liver but no sign of nodular lesions. Following admission to our hospital, he received liver supportive therapy with the discontinuation of ipragliflozin therapy. He was discharged from the hospital 18 days later with AST and ALT levels reduced to 20 U/L and 13 U/L, respectively. Based on the clinical presentation of this patient, it is highly important to monitor liver function along with other possible clinical complications (e.g., dehydration, ketosis, and urinary tract infection) associated with SGLT2 inhibitor therapy.

REFERENCES

1. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-25.

2. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-19.

3. Yilmaz Y, Younossi ZM. Obesity-Associated Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2014; 18: 19-31.

4. Parveen R, Agarwal NB, Kaushal N, Mali G, Raisuddin S. Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials. Expert Opin Pharmacother 2016; 17: 105-15.

5. Pichler WJ. Lymphocyte transformation test. Encyclopedia of Immunology 2014; 10.1007/978-3-642-27786-3_924-5

6. Honda Y, Imajo K, Kato T, Kessoku T, Ogawa Y, Tomeno W, Kato S, et al. The selective SGLT2 inhibitor Ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. PLoS ONE 2016; 11: e0146337. doi:10.1371/ journal.pone.0146337

7. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: The Update. Int J Mol Sci. 2015; Dec 24;17(1). pii: E14. doi: 10.3390/ijms17010014.

8. Teschke R, Danan G. Diagnosis and Management of Drug- Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease. Drug Saf 2016; 39: 729-44.

9. Tarantino G, Conca P, Basile V, Gentile A, Capone D, Polichetti G, Leo E. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007; 37: 410-15.